Christine Mundkur - MannKind Corp Director
| MNKD Stock | USD 4.18 0.01 0.24% |
Director
Ms. Christine Mundkur is Director of the company. Ms. Mundkur most recently served as chief executive officer and the nonvoting chairman of the board of directors for Impopharma Inc., a developer of complex formulations focused on inhalation pharmaceutical products. While at Impopharma, Ms. Mundkur led the transition of the company from a successful clinical research organization into a generic pharmaceutical inhalation development company. Her work included the internal development and filing of Abbreviated New Drug Applications of spray and inhalation products. Ms. Mundkur also held leadership positions as president and chief executive office of the US Division and head of commercial operations for North America for Sandoz, Inc. Earlier, she served as chief executive officer of Barr Laboratories, Inc., where she started her career as quality and regulatory counsel. In addition, Ms. Mundkur served as a strategic consultant advising several clients on global pharmaceutical business strategies since 2018.
| Age | 49 |
| Tenure | 6 years |
| Address | 1 Casper Street, Danbury, CT, United States, 06810 |
| Phone | 818 661 5000 |
| Web | https://www.mannkindcorp.com |
MannKind Corp Management Efficiency
The company has return on total asset (ROA) of 0.0172 % which means that it generated a profit of $0.0172 on every $100 spent on assets. This is way below average. MannKind Corp's management efficiency ratios could be used to measure how well MannKind Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of April 27, 2024, Return On Tangible Assets is expected to decline to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.03. At present, MannKind Corp's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 392.1 M, whereas Non Current Assets Total are forecasted to decline to about 87.1 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Christopher Causey | United Therapeutics | 55 | |
| Stephen Sherwin | Verastem | 66 | |
| Harold Wiens | Bio Techne Corp | 69 | |
| Steven Mento | Sangamo Therapeutics | 65 | |
| Raymond Dwek | United Therapeutics | 76 | |
| Timothy Barberich | Verastem | 70 | |
| Stewart Parker | Sangamo Therapeutics | 62 | |
| Paul Friedman | Verastem | 72 | |
| Pete Meyers | Immutep Ltd ADR | 46 | |
| Alpna Seth | Bio Techne Corp | 54 | |
| Frederic MD | Immutep Ltd ADR | 69 | |
| Stephen Biggar | Kiniksa Pharmaceuticals | 47 | |
| Rupert Vessey | Bio Techne Corp | 53 | |
| Elaine Heron | Biomarin Pharmaceutical | 70 | |
| Liz Anderson | Biomarin Pharmaceutical | N/A | |
| Henri Termeer | Verastem | 67 | |
| Gina Consylman | Verastem | 45 | |
| Lawrence Alleva | Adaptimmune Therapeutics Plc | 68 | |
| Alan Lewis | Biomarin Pharmaceutical | 71 | |
| Bryan Lawlis | Biomarin Pharmaceutical | 66 | |
| Brian Stuglik | Verastem | 59 | |
Management Performance
| Return On Asset | 0.0172 |
MannKind Corp Leadership Team
Elected by the shareholders, the MannKind Corp's board of directors comprises two types of representatives: MannKind Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MannKind. The board's role is to monitor MannKind Corp's management team and ensure that shareholders' interests are well served. MannKind Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MannKind Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Bedard, Senior Affairs | ||
| Michael Friedman, Independent Director | ||
| Lauren Sabella, Executive COO | ||
| McCauley JD, Chief Officer | ||
| Raymond Urbanski, Corporate Vice President Chief Medical Officer | ||
| David Thomson, Corporate Vice President General Counsel, Corporate Secretary | ||
| Linda Adreveno, Senior Vice President - Human Resources | ||
| MS MBA, Chief Officer | ||
| Matthew PharmD, Senior Unit | ||
| Ronald Consiglio, Independent Director | ||
| Michael Castagna, Chief Commercial Officer | ||
| Joseph Kocinsky, CTO and Sr. VP of Technical Operations | ||
| Sanjay MBA, Executive Operations | ||
| Steven Binder, CFO, Principal Accounting Officer | ||
| Thomas MD, Chief Officer | ||
| Dr JD, General VP | ||
| David MacCallum, Independent Director | ||
| Burkhard MD, Executive Officer | ||
| Stuart Tross, Chief People Officer | ||
| Kent Kresa, Lead Independent Director | ||
| Alfred Mann, Founder and Executive Chairman | ||
| Rose Alinaya, Chief Accounting Officer | ||
| Juergen Martens, COO | ||
| Christine Mundkur, Director | ||
| Michael PharmD, CEO Director | ||
| Henry Nordhoff, Independent Director | ||
| Rosabel Alinaya, Acting CFO, Senior Vice President Chief Accounting Officer | ||
| Diane Palumbo, Corporate Vice President - Human Resources | ||
| Patrick McCauley, Chief Commercial Officer | ||
| James Shannon, Director | ||
| Matthew Pfeffer, Corporate Vice President and CFO |
MannKind Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MannKind Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0172 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 1.21 B | ||||
| Shares Outstanding | 270.76 M | ||||
| Shares Owned By Insiders | 1.52 % | ||||
| Shares Owned By Institutions | 50.33 % | ||||
| Number Of Shares Shorted | 31.05 M | ||||
| Price To Earning | 2.27 X | ||||
| Price To Sales | 5.65 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MannKind Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For information on how to trade MannKind Stock refer to our How to Trade MannKind Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for MannKind Stock analysis
When running MannKind Corp's price analysis, check to measure MannKind Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MannKind Corp is operating at the current time. Most of MannKind Corp's value examination focuses on studying past and present price action to predict the probability of MannKind Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MannKind Corp's price. Additionally, you may evaluate how the addition of MannKind Corp to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is MannKind Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MannKind Corp. If investors know MannKind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MannKind Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share 0.745 | Quarterly Revenue Growth 0.622 | Return On Assets 0.0172 |
The market value of MannKind Corp is measured differently than its book value, which is the value of MannKind that is recorded on the company's balance sheet. Investors also form their own opinion of MannKind Corp's value that differs from its market value or its book value, called intrinsic value, which is MannKind Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MannKind Corp's market value can be influenced by many factors that don't directly affect MannKind Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MannKind Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if MannKind Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MannKind Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.